PHARMACEUTICAL COMPOSITION WHICH CONTAINS gamma-butyrobetaine, FOR THE TREATMENT OF L-CARNITINE BY LACK induced syndromes.

摘要

Further to the discovery that the syndromes induced by L-carnitine deficiency are provoked by defects in the gamma butyrobetaine biosynthesis in skeletal and heart muscles, whereas the liver and kidney of the patients exhibiting such syndromes retain unaltered their L-carnitine-making ability, there are disclosed a gamma-butyrobetaine-containing composition and a therapeutical method based on gamma-butyrobetaine administration for the treatment of such patients.